Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
25 November 2024 - 10:15PM
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO,
TSX: APS), a clinical-stage precision oncology company developing
highly differentiated oral targeted agents to treat hematologic
malignancies, today announced the closing of its previously
announced "reasonable best efforts" public offering with
participation from the CEO and existing and new healthcare focused
investors for the purchase and sale of 40,000,000 common shares at
a price of $0.20 per share and warrants to purchase up to
20,000,000 common shares (the “Offering”). The warrants have an
exercise price of $0.25 per share, are exercisable
immediately and will expire five years from the issuance date. The
Company received aggregate gross proceeds of $8 million,
before deducting placement agent fees and other offering expenses,
and intends to use the net proceeds from this Offering for working
capital and general corporate purposes.
A.G.P./Alliance Global Partners is acting as the
sole placement agent for the Offering.
The securities described above were offered
pursuant to a registration statement on Form S-1 (File No.
333-281201) previously filed with the Securities and Exchange
Commission ("SEC") on August 2, 2024, as amended, which was
declared effective on November 21, 2024. This Offering was made
only by means of a prospectus forming part of the effective
registration statement. A preliminary prospectus relating to the
Offering has been filed with the SEC. An electronic copy of the
final prospectus relating to the Offering may be obtained on the
SEC's website located at http://www.sec.gov and may also be
obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue,
28th Floor, New York, NY 10022, or by telephone at (212) 624-2060,
or by email at prospectus@allianceg.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to developing precision medicines
addressing unmet medical needs in oncology, with an initial focus
on hematology. The Company's small molecule cancer therapeutics
pipeline includes products designed to provide single agent
efficacy and to enhance the efficacy of other anti-cancer therapies
and regimens without overlapping toxicities. The Company’s lead
clinical-stage, oral kinase inhibitor tuspetinib (TUS) has
demonstrated activity as a monotherapy and in combination therapy
in patients with relapsed or refractory acute myeloid leukemia
(AML), and is being developed as a frontline triplet therapy in
newly diagnosed AML. For more information, please visit
www.aptose.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws,
including, but not limited to, statements relating to the intended
use of proceeds and statements relating to the Company’s plans,
objectives, expectations and intentions and other statements
including words such as “continue”, “expect”, “intend”, “will”,
“hope” “should”, “would”, “may”, “potential” and other similar
expressions. Such statements reflect our current views with respect
to future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us, are inherently subject to
significant market and other conditions, business, economic,
competitive, political and social uncertainties and contingencies.
Many factors could cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements described in this press release. Such
factors could include, among others: our ability to obtain the
capital required for research and operations; the inherent risks in
early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the
progress of our clinical trials; our ability to find and enter into
agreements with potential partners; our ability to attract and
retain key personnel; changing market and economic conditions;
unexpected manufacturing defects and other risks detailed from
time-to-time in our ongoing current reports, quarterly filings,
annual information forms, annual reports and annual filings with
Canadian securities regulators and the United States Securities and
Exchange Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
For further information, please contact:
Aptose Biosciences Inc. |
|
Susan Pietropaolo |
|
Corporate Communications & Investor Relations |
|
201-923-2049 |
|
spietropaolo@aptose.com |
|
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024